Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Gattermann

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
Annals of Hematology|March 9, 2022
Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysisA Boquoi, S M Banahan, A Mohring, et al.
Leukemia|February 3, 2007
Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classificationA Matsuda, U Germing, I Jinnai, et al.
European Journal of Haematology|June 20, 2002
Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cellsM Aivado, A Rong, M Stadler, et al.
Annals of Hematology|October 18, 2012
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overloadF Nolte, B Höchsmann, A Giagounidis, et al.
Leukemia|December 25, 2004
Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinibF Neumann, N Teutsch, S Kliszewski, et al.
Leukemia|August 26, 2006
The JAK2 V617F mutation is rare in RARS but common in RARS-TM M Ceesay, N C Lea, W Ingram, et al.
Leukemia|July 11, 2008
High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemiaJ W Tyner, M M Loriaux, H Erickson, et al.
European Journal of Medical Research|August 4, 2011
The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tractC Matuschek, Edwin Bölke, M Peiper, et al.
Annals of Hematology|June 9, 2025
Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS)K Nachtkamp, F Schulz, A Kasprzak, et al.
Ecancermedicalscience|January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an updateL R Silverman, P Fenaux, G J Mufti, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Annals of Hematology|March 9, 2022
Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysisA Boquoi, S M Banahan, A Mohring, et al.
Leukemia|February 3, 2007
Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classificationA Matsuda, U Germing, I Jinnai, et al.
European Journal of Haematology|June 20, 2002
Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cellsM Aivado, A Rong, M Stadler, et al.
Annals of Hematology|October 18, 2012
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overloadF Nolte, B Höchsmann, A Giagounidis, et al.
Leukemia|December 25, 2004
Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinibF Neumann, N Teutsch, S Kliszewski, et al.
Leukemia|August 26, 2006
The JAK2 V617F mutation is rare in RARS but common in RARS-TM M Ceesay, N C Lea, W Ingram, et al.
Leukemia|July 11, 2008
High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemiaJ W Tyner, M M Loriaux, H Erickson, et al.
European Journal of Medical Research|August 4, 2011
The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tractC Matuschek, Edwin Bölke, M Peiper, et al.
Annals of Hematology|June 9, 2025
Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS)K Nachtkamp, F Schulz, A Kasprzak, et al.
Ecancermedicalscience|January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an updateL R Silverman, P Fenaux, G J Mufti, et al.
Pageof 11